文献速递前列腺癌

两种亮丙瑞林剂型延迟给药对睾酮抑制的影响:原位凝胶与微球制剂的美国临床数据分析

Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
PubMed 文献 · J Urol · 2020-10-22

该回顾性研究分析了美国前列腺癌患者使用原位凝胶或微球剂型亮丙瑞林时延迟给药对睾酮抑制的影响。共纳入2038例凝胶组和8360例微球组患者,超过80%注射在28天月定义下延迟。微球剂型睾酮超过50/20 ng/dl的风险是凝胶的1.5倍,凝胶剂型睾酮抑制更优。

要点

  • 亮丙瑞林延迟给药常见,超过80%注射在28天月定义下延迟。
  • 微球剂型睾酮超过50/20 ng/dl的风险是凝胶的1.5倍。
  • 凝胶剂型在28天和延长月定义下均显示更高的睾酮抑制率。

核心结论

  • 亮丙瑞林治疗常延迟给药,凝胶剂型比微球剂型有更高比例的患者睾酮达到50 ng/dl或以下及20 ng/dl或以下。

研究设计与样本

  • 回顾性分析美国前列腺癌患者记录,比较凝胶与微球剂型亮丙瑞林延迟给药对睾酮抑制的影响。
  • 凝胶组2038例,微球组8360例。
  • 采用两种「月」定义:28天月(第28、84、112或168天后延迟)和延长月(第32、97、128和194天后延迟)。

主要发现

  • 超过80%的注射在28天月定义下延迟,超过27%在延长月定义下延迟。
  • 28天月延迟注射中,睾酮>50 ng/dl的比例凝胶组10%、微球组14%;>20 ng/dl的比例凝胶组25%、微球组33%。
  • 延长月延迟注射中,睾酮>50 ng/dl的比例凝胶组18%、微球组25%;>20 ng/dl的比例凝胶组34%、微球组44%。
  • 微球剂型亮丙瑞林睾酮>50/20 ng/dl的可能性是凝胶的1.5倍。
  • 最小二乘均值睾酮:28天月凝胶34 ng/dl vs 微球46 ng/dl;延长月凝胶48 ng/dl vs 微球76 ng/dl。

临床怎么用

  • 临床应重视亮丙瑞林给药依从性,延迟给药常见且影响睾酮抑制。
  • 选择剂型时需考虑释放技术差异,凝胶剂型可能提供更优的睾酮抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nonadherence to dosing schedules for androgen deprivation therapy increases the risk of testosterone escape for patients with prostate cancer. Two approved formulations of leuprolide acetate, the most commonly prescribed androgen deprivation therapy in the United States, use different extended release delivery technologies: an in situ gel and microspheres. We evaluated the prevalence and impact of late dosing on testosterone suppression for gel and microsphere formulations of leuprolide acetate. MATERIALS AND METHODS: We retrospectively analyzed records of patients with prostate cancer treated with gel or microsphere delivery of leuprolide acetate. Analyses used 2 definitions of "month," "28-day" (late dosing after day 28, 84, 112 or 168) and "extended" (late dosing after day 32, 97, 128 and 194). Frequencies of late dosing and associated testosterone values were calculated. RESULTS: A total of 2,038 patients received gel and 8,360 received microsphere formulations of leuprolide acetate. More than 80% and 27% of injections were late for 28-day and extended month, respectively. For 28-day month late injections 10% (gel delivery) and 14% (microsphere delivery) of testosterone values were above 50 ng/dl, and 25% (gel) vs 33% (microsphere) were above 20 ng/dl. For extended month 18% (gel) vs 25% (microsphere) were above 50 ng/dl, and 34% (gel) vs 44% (microsphere) were above 20 ng/dl. Microsphere leuprolide acetate was 1.5 times more likely to have testosterone above 50/20 ng/dl vs gel. Least square mean testosterone was 34 ng/dl (gel) vs 46 ng/dl (microsphere) for 28-day month, and 48 ng/dl (gel) vs 76 ng/dl (microsphere) for extended month. CONCLUSIONS: Leuprolide acetate therapies were frequently administered late. Gel formulation demonstrated higher rates of testosterone 50 ng/dl or less and 20 ng/dl or less than microsphere formulation. Optimal testosterone suppression can impact prostate cancer progression and patient survival, and differences in extended release technology for androgen deprivation therapy appear relevant.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Hafron JM, Tagawa ST, et al. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2020. PMID: 33090917. doi:10.1097/JU.0000000000001392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。